Can Do MS’s programs enhance and complement traditional models of care by focusing on the physical, emotional, social, occupational, spiritual and intellectual aspects aspects of living with MS. We believe that pharmaceutical therapies are one part of the overall care plan for people living with MS. We work to educate those with MS, as well as medical and pharmaceutical professionals, on our whole-person, whole-health, whole-community philosophy to maximizing health and living with MS.
Can Do MS’s Relationship with the Pharmaceutical Industry
Many pharmaceutical companies recognize that our programs complement the therapies they offer. When pharmaceutical companies provide support to our programs that require outside funding, and other online resources, they do not have input into the content of these programs, nor do they direct the use of the funds spent in the service of our mission.
In 2016, Can Do MS’s total revenue was $1,767,375; below is a breakdown of pharmaceutical contributions.
2016 Pharmaceutical Contributions:
- Total Pharmaceutical Revenue: $856,200
- Percentage of Total Organizational Revenue: 48%
- Event Sponsorship: $700,477
- Program Grants: $681,096
Contributions by companies without an MS product on market in 2016:
- Genentech, Inc.: $60,000
Contributions by companies with an MS product on market in 2016:
- Acorda Therapeutics, Inc.: $10,000
- Biogen: $269,000
- EMD Serono, Inc.: $35,000
- Genzyme Corporation: $134,000
- Novartis Pharmaceuticals Corp.: $130,000
- Mallinckrodt: $35,000
- Teva Pharmaceuticals: $111,500
- Sanofi Genzyme: $61,700
- Allergen: $5,000
- Bayer: $5,000